Three scientists were recognized by the Lasker Awards for their work on the GLP-1 hormone. Others were honored for work to ...

It’s a brain disease,” a prominent obesity doctor explained on a “60 Minutes” episode about the drugs. “Obesity is disease” ...

Terns Pharmaceuticals’ decision to drop its liver disease ambitions may yet pay off, after the biotech posted phase 1 data ...

GLP-1 based drugs are transforming the treatment of obesity and opening up new avenues for addressing heart disease, ...

Three scientists are honored for developing a class of blockbuster weight-loss drugs. Is a Nobel prize on the way?

Obesity-focused biotech BioAge Labs said on Wednesday it was seeking a valuation of as much as $587 million in its initial ...

The medtech industry hopes to capitalise on increased awareness about the obesity space to promote multidisciplinary ...

Australian researchers said that supervised diets with intermittent fasting were for children with serious health conditions, ...

The release of early-stage data on three oral weight loss drug candidates hints at which companies have the strongest hand, ...

Unfortunately, too many insurers — including Medicare — still see obesity as a cosmetic issue instead of the disease that it ...

Certain blockbuster weight-loss drugs have been found to protect the heart in significant ways, and new research suggests ...

GLP-1 drugs like Ozempic and Wegovy may help reduce the risk of cardiovascular disease and prevent more than 34,000 heart ...